SKIP TO CONTENT
About Abbott
Contact
International | eng
Country Language

CARDIOVASCULAR

International | eng
Country Language

XIENCE™ Family of Drug-Eluting Stents

The World's Leading Drug-Eluting Stents (DES), with Unparalleled Clinical Outcomes¹

Market Leading Everolimus

Market-Leading Everolimus

The market-leading choice for XIENCE™ Stent is everolimus, which is a proven therapeutic drug.²

An ideal drug for DES has these characteristics:

  • Safe over the long term
  • Stable over time
  • Compatible with polymer
  • Cytostatic and anti-inflammatory
  • Effective at varying doses for a wide therapeutic window

The everolimus drug provides all these features.


Everolimus Elution Rate Matches Restenosis Cascade for Optimal Endothelization Rate3

The release of everolimus aligns with the vessel's restenosis cascade. This, in turn, maximizes the drug's efficacy against restenosis and minimizes the drug's effect of re-endothelialization, which facilitates vessel restoration and function.

 

Everolimus Elution Correlates to Restenosis Cascade
 

The Xience Stent drug elution profile shows that 100% of the drug is eluted at 120 days.

XIENCE™ Stent Uses Low Dose of Everolimus3,4

Everolimus is a well established anti-proliferative drug. The concentration of everolimus used with XIENCE™ Stent is low, at 100 µg/cm². These histological images below show healthy, fully healed vessels at a concentration that is 8x the dose used on the XIENCE™ stent. Images were gathered using a pre-clinical animal model.


Everolimus Safety at 8x Drug Dose
 

Everolimus safety at 8x its regular dose on XIENCE™ DES

References

  1. Zanchin C, et al. JACC Cardiovasc Interv. 2019;12(17):1665-1675. Serruys P, et al. N Engl J Med. 2010;363:136-146. Shiomi H, et al. JACC Cardiovasc Interv. 2019;12:637-647. Kufner S, et al. Circulation. 2019:139(3):325-333. Palmerini T, et al. Lancet. 2013;379:1393-1402. Bangalore S, et al. Circulation. 2012;125:2873-2891. Bangalore S, et al. Circ Cardiovasc Interv. 2013;6(6):378-390. Pilgrim T, et al. Lancet. 2014;384:2111-2122. Pilgrim T, et al. Lancet. 2018;392:737-746. Data on file at Abbott.
  2. XIENCE Skypoint™ Stent Instruction For Use (IFU). Refer to IFU for additional information. 
  3. Perkins L, et al. J Interven Cardiol. 2009;22:S28-S40; Bennett J, Biologics: Targets and Therapy. 2013;7:149-159; Meredith I et al. J Am Cardiol Intv. 2009;2:977-985.
  4. Data on file at Abbott.
Manuals & Technical Resources

Manuals & Technical Resources

Order Cardiovascular Products

Cardiovascular Products

Customer Service

Customer Service

MAT-2101779 v2.0

POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
Abbott logo

Information contained herein for distribution outside the U.S. only.

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2025 Abbott. All Rights Reserved.

MAT-2001111 v8.0

Disclaimer

You are about to enter an Abbott country- or region-specific website. 

Please be aware that the website you have requested is intended for the residents of a particular country or countries, as noted on that site. As a result, the site may contain information on pharmaceuticals, medical devices and other products or uses of those products that are not approved in other countries or regions

Do you wish to continue and enter this website? 

YES

MAT-2305078 v1.0